Dallas Nephrology Associates

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• IgA nephropathy1 trial
• Peripheral artery disease1 trial

Phase

• Phase 2/31 trial
• Phase 41 trial

Status

• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• CSL Behring1 trial
• Travere Therapeutics, Inc.1 trial

Running trials

• Active, not recruiting

  Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

  NCT07219121· Phase 4· Travere Therapeutics, Inc.· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

  Contact: Trial Registration Coordinator

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Peripheral artery disease1 recruiting